{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:33:55Z","timestamp":1790732035297,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1684\/bdc.2010.1108","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:58:33Z","timestamp":1565726313000},"page":"937-949","source":"Crossref","is-referenced-by-count":5,"title":["Propri\u00e9t\u00e9s antitumorales du bisphosphonate zol\u00e9dronate et implications th\u00e9rapeutiques potentielles en clinique"],"prefix":"10.1016","volume":"97","author":[{"given":"P.","family":"Cl\u00e9zardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2010.1108_bib0005","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10585-007-9112-8","article-title":"Bone metastasis: pathogenesis and therapeutic implications","volume":"24","author":"Cl\u00e9zardin","year":"2007","journal-title":"Clin Exp Metastasis"},{"key":"10.1684\/bdc.2010.1108_bib0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1138\/20080341","article-title":"An update on the pharmacology of bisphosphonates and analogues with lower bone affinity","volume":"5","author":"Coxon","year":"2008","journal-title":"IBMS Bonekey"},{"key":"10.1684\/bdc.2010.1108_bib0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","article-title":"A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen containing bisphosphonates","volume":"147","author":"M\u00f6nkk\u00f6nen","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1684\/bdc.2010.1108_bib0020","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Brit J Cancer"},{"key":"10.1684\/bdc.2010.1108_bib0025","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2010.1108_bib0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2007.07.007","article-title":"Bisphosphonates in cancer therapy","volume":"257","author":"Stresing","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1684\/bdc.2010.1108_bib0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/CAD.0b013e3282f632bf","article-title":"Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth","volume":"19","author":"M\u00f6nkk\u00f6nen","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1684\/bdc.2010.1108_bib0040","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bone.2009.08.010","article-title":"The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro","volume":"45","author":"Mitrofan","year":"2009","journal-title":"Bone"},{"key":"10.1684\/bdc.2010.1108_bib0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2009.06.003","article-title":"Zoledronic acid induces apoptosis and changes the TRAIL\/OPG ratio in breast cancer cells","volume":"287","author":"Rachner","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1684\/bdc.2010.1108_bib0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ijc.24710","article-title":"Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha\/VEGF signaling pathways in human breast cancer cells","volume":"126","author":"Tang","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1684\/bdc.2010.1108_bib0055","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.bjp.0706373","article-title":"The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells","volume":"146","author":"Inoue","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1684\/bdc.2010.1108_bib0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jbmr.5650110415","article-title":"Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates","volume":"11","author":"Endo","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1684\/bdc.2010.1108_bib0065","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/0008-5472.540.65.2","article-title":"Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model","volume":"65","author":"Hashimoto","year":"2005","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.lungcan.2007.08.026","article-title":"Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers","volume":"59","author":"Li","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1684\/bdc.2010.1108_bib0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2008.09.026","article-title":"Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model","volume":"274","author":"Koto","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1684\/bdc.2010.1108_bib0080","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/cncr.21530","article-title":"Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice","volume":"104","author":"Ory","year":"2005","journal-title":"Cancer"},{"key":"10.1684\/bdc.2010.1108_bib0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bone.2005.02.020","article-title":"Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma","volume":"37","author":"Heymann","year":"2005","journal-title":"Bone"},{"key":"10.1684\/bdc.2010.1108_bib0090","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1158\/0008-5472.CAN-07-1882","article-title":"Amino-bisphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma","volume":"67","author":"Melani","year":"2007","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1684\/bdc.2010.1108_bib0100","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"Corey","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0105","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer","volume":"100","author":"Ottewell","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2010.1108_bib0110","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ijc.24756","article-title":"Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model","volume":"126","author":"Ottewell","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1684\/bdc.2010.1108_bib0115","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse models","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/1535-7163.MCT-08-0874","article-title":"Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice","volume":"8","author":"Yamada","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1684\/bdc.2010.1108_bib0125","first-page":"5380","article-title":"Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice","volume":"9","author":"Yano","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/CAD.0b013e3282f632bf","article-title":"Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth","volume":"19","author":"M\u00f6nkk\u00f6nen","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1684\/bdc.2010.1108_bib0135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubin\u00e9","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2010.1108_bib0140","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1158\/0008-5472.CAN-04-4188","article-title":"Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo","volume":"65","author":"van der Pluijm","year":"2005","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0145","doi-asserted-by":"crossref","first-page":"8945","DOI":"10.1158\/0008-5472.CAN-08-2195","article-title":"Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo","volume":"68","author":"Fournier","year":"2008","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0150","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/0008-5472.CAN-04-3601","article-title":"Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and. paclitaxel against experimental bone metastasis of human prostate cancer","volume":"65","author":"Kim","year":"2005","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0155","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1158\/1078-0432.853.11.2","article-title":"A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon a\/b-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo","volume":"11","author":"Yuasa","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrc2621","article-title":"The metastatic niche: adapting the foreign soil","volume":"9","author":"Psaila","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1684\/bdc.2010.1108_bib0165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1538-7836.2006.02259.x","article-title":"Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signalling pathways","volume":"5","author":"Hasmim","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1684\/bdc.2010.1108_bib0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","article-title":"Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients","volume":"25","author":"Vincenzi","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"10.1684\/bdc.2010.1108_bib0175","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.4049\/jimmunol.0901085","article-title":"Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen","volume":"183","author":"Vantourout","year":"2009","journal-title":"J Immunol"},{"key":"10.1684\/bdc.2010.1108_bib0180","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-008-0521-6","article-title":"In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients","volume":"58","author":"Santini","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1684\/bdc.2010.1108_bib0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3960\/jslrt.46.11","article-title":"Human gammadelta T cells and tumor immunotherapy","volume":"46","author":"Tanaka","year":"2007","journal-title":"J Clin Exp Hematopathol"},{"key":"10.1684\/bdc.2010.1108_bib0195","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00262-008-0571-9","article-title":"Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model","volume":"58","author":"Yuasa","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1684\/bdc.2010.1108_bib0200","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1021\/jm801003y","article-title":"Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism","volume":"51","author":"Simoni","year":"2008","journal-title":"J Med Chem"},{"key":"10.1684\/bdc.2010.1108_bib0205","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.4049\/jimmunol.173.11.6767","article-title":"Characterization of tumor reactivity of human Vgamma9Vdelta2 gamma delta T cells in vitro and in SCID mice in vivo","volume":"173","author":"Kabelitz","year":"2004","journal-title":"J Immunol"},{"issue":"1","key":"10.1684\/bdc.2010.1108_bib0210","first-page":"74s","article-title":"The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST","volume":"69","author":"Eidtmann","year":"2009","journal-title":"Cancer Res"},{"key":"10.1684\/bdc.2010.1108_bib0215","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrc2375","article-title":"Detection, clinical relevance and specific biological properties of disseminating tumour cells","volume":"8","author":"Pantel","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1684\/bdc.2010.1108_bib0220","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1684\/bdc.2010.1108_bib0225","first-page":"S40","article-title":"Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer","volume":"106","author":"Rack","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"10.1684\/bdc.2010.1108_bib0230","first-page":"20s","article-title":"Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1108_bib0235","doi-asserted-by":"crossref","unstructured":"Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-Macgregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010 ; (sous presse)","DOI":"10.1016\/S1470-2045(10)70054-1"},{"key":"10.1684\/bdc.2010.1108_bib0240","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1172\/JCI28568","article-title":"The stem cell niches in bone","volume":"116","author":"Yin","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1684\/bdc.2010.1108_bib0245","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115307931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115307931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T16:15:21Z","timestamp":1664122521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115307931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0007455115307931"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2010.1108","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}